Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Hepatitis B treatment: Current best practices, avoiding resistance.

Gish RG.

Cleve Clin J Med. 2009 May;76 Suppl 3:S14-9. doi: 10.3949/ccjm.76.s3.04.

2.

Chronic hepatitis B: preventing, detecting, and managing viral resistance.

Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y.

Clin Gastroenterol Hepatol. 2008 Mar;6(3):268-74. doi: 10.1016/j.cgh.2007.12.043. Review.

PMID:
18328434
3.

Therapeutic strategies for chronic hepatitis B virus infection in 2008.

Khokhar A, Afdhal NH.

Am J Med. 2008 Dec;121(12 Suppl):S33-44. doi: 10.1016/j.amjmed.2008.09.027.

PMID:
19185073
4.

Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.

Cheng PN, Chang TT.

Expert Rev Anti Infect Ther. 2008 Oct;6(5):569-79. doi: 10.1586/14787210.6.5.569. Review.

PMID:
18847396
5.
6.

Current treatment of chronic hepatitis B: benefits and limitations.

Perrillo RP.

Semin Liver Dis. 2005;25 Suppl 1:20-8. Review.

PMID:
16103978
7.

Treatment of chronic hepatitis B: are we ready for combination therapy?

Seetharam A, Lisker-Melman M.

Curr Gastroenterol Rep. 2009 Feb;11(1):22-7.

PMID:
19166655
8.

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.

Shouval D, Lai CL, Chang TT, Cheinquer H, Martin P, Carosi G, Han S, Kaymakoglu S, Tamez R, Yang J, Tenney D, Brett-Smith H.

J Hepatol. 2009 Feb;50(2):289-95. doi: 10.1016/j.jhep.2008.10.017. Epub 2008 Nov 19.

PMID:
19070393
9.

Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?

Suzuki Y, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Miyakawa Y, Kumada H.

J Gastroenterol Hepatol. 2009 Mar;24(3):429-35. doi: 10.1111/j.1440-1746.2008.05760.x. Epub 2009 Feb 15.

PMID:
19226381
10.

Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance.

Kurashige N, Ohkawa K, Hiramatsu N, Yakushijin T, Mochizuki K, Oze T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Fukuda K, Oshita M, Mita E, Fukui H, Nagase T, Yoshihara H, Imai Y, Kato M, Kashihara T, Hayashi N.

J Gastroenterol. 2009;44(8):864-70. doi: 10.1007/s00535-009-0076-0. Epub 2009 May 28.

PMID:
19475333
11.

Pathobiology of HBV mutants and clinical impact for treatment monitoring.

Si Ahmed SN, Zoulim F.

Expert Rev Anti Infect Ther. 2009 Apr;7(3):309-20. doi: 10.1586/eri.09.10. Review.

PMID:
19344244
12.

Therapy of chronic hepatitis B: trends and developments.

Delaney WE 4th, Borroto-Esoda K.

Curr Opin Pharmacol. 2008 Oct;8(5):532-40. doi: 10.1016/j.coph.2008.09.008. Epub 2008 Oct 6. Review.

PMID:
18835366
13.

[Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases].

Lee HJ, Eun JR, Lee CH, Hwang JS, Suh JI, Kim BS, Jang BK.

Korean J Hepatol. 2009 Jun;15(2):179-92. doi: 10.3350/kjhep.2009.15.2.179. Korean.

14.

Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: phase II clinical study in Japan.

Kobashi H, Takaguchi K, Ikeda H, Yokosuka O, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Sakaguchi K, Shiratori Y.

J Gastroenterol Hepatol. 2009 Feb;24(2):255-61. doi: 10.1111/j.1440-1746.2008.05593.x.

PMID:
19215336
15.

Treatment of chronic hepatitis B and the implications of viral resistance to therapy.

Mauss S, Wedemeyer H.

Expert Rev Anti Infect Ther. 2008 Apr;6(2):191-9. doi: 10.1586/14787210.6.2.191. Review.

PMID:
18380601
16.

Management of treatment failure in chronic hepatitis B.

Zoulim F, Locarnini S.

J Hepatol. 2012;56 Suppl 1:S112-22. doi: 10.1016/S0168-8278(12)60012-9. Review.

PMID:
22300461
17.

Strategies for managing coinfection with hepatitis B virus and HIV.

Sherman M.

Cleve Clin J Med. 2009 May;76 Suppl 3:S30-3. doi: 10.3949/ccjm.76.s3.07.

18.

Benefits and risks of combination therapy for hepatitis B.

Terrault NA.

Hepatology. 2009 May;49(5 Suppl):S122-8. doi: 10.1002/hep.22921.

PMID:
19399796
19.

Antiviral therapy of chronic hepatitis B: prevention of drug resistance.

Fournier C, Zoulim F.

Clin Liver Dis. 2007 Nov;11(4):869-92, ix. Review.

PMID:
17981233
20.

Hepatitis B therapies and antiviral resistance detection and management.

Holness G, Carriero DC, Dieterich DT.

Expert Rev Gastroenterol Hepatol. 2009 Dec;3(6):693-9. doi: 10.1586/egh.09.64. Review.

PMID:
19929588

Supplemental Content

Support Center